Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow ADIAL PHARMACEUTICALS, INC.

Get SEC filing alerts via email and in your feed for ADIAL PHARMACEUTICALS, INC.

ADIL ADIWW

ADIAL PHARMACEUTICALS, INC.

About ADIAL PHARMACEUTICALS, INC.

Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing AD04, a treatment for alcohol use disorder (AUD) that leverages genetic screening to identify suitable patients. With a significant market opportunity, Adial aims to address the needs of approximately 30 million U.S. individuals with AUD. The company is advancing its clinical trials and regulatory strategy, emphasizing a novel approach that allows for controlled drinking without requiring abstinence.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from ADIAL PHARMACEUTICALS, INC.

1
1
ADIAL PHARMACEUTICALS, INC. Adial Pharmaceuticals Reports $2M Net Loss, Enters Collaboration with Molteni Farmaceutici

Via official filing (AI summary) | 27 days ago | 0 comments

2
1
ADIAL PHARMACEUTICALS, INC. Adial Pharmaceuticals Reports $8M Net Loss for Fiscal Year 2025, Faces Funding Challenges

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
ADIAL PHARMACEUTICALS, INC. Adial Pharmaceuticals Reports Decreased Net Loss and Increased Cash Reserves in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
ADIAL PHARMACEUTICALS, INC. Adial Pharmaceuticals Reports Decreased Net Loss and Increased Cash Reserves for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
ADIAL PHARMACEUTICALS, INC. Adial Pharmaceuticals Reports Improved Net Loss of $2.23 Million for Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
ADIAL PHARMACEUTICALS, INC. Adial Pharmaceuticals Reports $13.2 Million Net Loss for 2024, Plans Additional Phase 3 Trials for AD04

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
ADIAL PHARMACEUTICALS, INC. Adial Pharmaceuticals Reports Mixed Financial Results, Raises Concerns Over Liquidity

Via official filing (AI summary) | over 1 year ago | 0 comments